Leerink Partners Reiterates Buy Rating on UnitedHealth Group

Leerink Partners has reiterated its Buy rating on UnitedHealth Group Incorporated (NYSE: UNH) with a price target of $462. This update came on June 17, 2026, as the stock traded around $407.65.

What Changed in Leerink Partners' UnitedHealth Group Position

On June 17, 2026, Leerink Partners maintained its Buy rating on UnitedHealth Group, setting a price target of $462. This decision reflects the firm's continued confidence in the company's prospects.

Other Institutional Activity in UnitedHealth Group

BlackRock, Inc. reduced its stake in UnitedHealth Group by 1,276,021 shares, now holding 73,467,531 shares valued at approximately $19.88 billion. Vanguard Capital Management LLC added a significant number of shares, bringing its total to 58,870,777 shares worth around $15.93 billion. State Street Corp slightly increased its holdings by 100,016 shares, totaling 45,332,186 shares valued at $12.27 billion. Capital World Investors significantly boosted its position by 5,192,373 shares, resulting in 27,783,415 shares worth about $7.52 billion. Geode Capital Management, LLC increased its holdings by 977,105 shares, now holding 22,768,695 shares valued at $6.14 billion.

UnitedHealth Group Incorporated Stock Up 0.4%

Shares of NYSE:UNH traded near $407.65. UnitedHealth Group has a market cap of approximately $370.2 billion and a P/E ratio of 30.67. The stock's 52-week low is $234.60, and its high is $415.98, with a 50-day moving average of $368.93 and a 200-day moving average of $332.65. The company has a beta of 0.65, indicating lower volatility compared to the market.

Recent Earnings

UnitedHealth Group reported revenue of $449.71 billion with a modest growth rate of 2%. The company achieved an EPS of $13.29, a net margin of 2.68%, and a return on equity of 12.18%. The next earnings report is scheduled for July 16, 2026.

Dividend

UnitedHealth Group offers an annual dividend rate of $9.28, yielding 2.28%. The dividend payout ratio stands at 66.57%.

Insider Buying and Selling at UnitedHealth Group Incorporated

Recent insider activity shows Patrick Hugh Conway, CEO of Optum, sold 687 shares on June 5, 2026, at an average price of $399.47. EVP & Chief Legal Officer Christopher Zaetta sold 134 shares on June 3, 2026, at $377. Patrick Hugh Conway also sold 204 shares on June 2, 2026, at $377.92.

Analysts Set New Price Targets

On June 17, 2026, Leerink Partners maintained a Buy rating on UnitedHealth Group with a price target of $462. Mizuho and JP Morgan also maintained Buy ratings with targets of $460 and $466, respectively, on June 8, 2026. Morgan Stanley set a target of $453 on June 4, 2026, while B of A Securities upgraded to a Buy with a $450 target the same day. The consensus recommendation remains a Buy with a mean target price of $407.38 among 26 analysts.

About UnitedHealth Group

UnitedHealth Group Incorporated is a major healthcare company based in Eden Prairie, Minnesota. It operates through segments like Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, offering a range of services from care management to pharmacy care. Led by CEO Stephen J. Hemsley, UnitedHealth employs around 390,000 people worldwide.

Bottom Line

Leerink Partners' reiteration of its Buy rating on UnitedHealth Group signals ongoing confidence in the company's performance. With a strong market position and consistent earnings, UnitedHealth remains a key player in the healthcare sector. As always, remember that analyst ratings are one of many factors investors consider, and this report reflects views as of June 17, 2026.